Zydus Lifesciences Acquisition Worth ₹156.3 Cr
Zydus Lifesciences completed the acquisition of Assertio Holdings Inc. for ₹156.35 Crore. Assertio becomes a wholly owned subsidiary, expanding Zydus' oncology portfolio.
- Value
- ₹156.3 Cr
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements with these filters
Zydus Lifesciences completed the acquisition of Assertio Holdings Inc. for ₹156.35 Crore. Assertio becomes a wholly owned subsidiary, expanding Zydus' oncology portfolio.
Zydus Lifesciences completed the acquisition of Assertio Holdings via a cash tender offer. Assertio will become a wholly owned subsidiary, expanding Zydus' global portfolio.
Zydus Lifesciences is acquiring Assertio Holdings for approximately ₹1580.8 Crore in cash. The deal establishes an immediate U.S. specialty oncology commercial footprint and infrastructure.
Zydus Lifesciences' subsidiary, Amplitude SAS, has acquired a 100% stake in French medical equipment distributor FBC Medical for ₹7.79 Crore. The acquisition aims to internalize commercial capabilities and reduce long-term distribution costs in France. The transaction was completed on April 30, 2026.
Zydus Lifesciences' step-down subsidiary, Amplitude SAS, completed the 100% acquisition of French medical equipment distributor Aptitude Orthopedie for ₹4.01 Crore. The move internalizes commercial capabilities in France to reduce long-term selling costs and eliminate third-party commission fees.
Zydus Lifesciences Limited's indirect subsidiary, Amplitude SAS, acquired 100% of French medical equipment distributor FBC Medical for Euro 700,000 (₹7.77 Crore). The acquisition, completed on April 30, 2026, aims to internalize commercial capabilities and reduce long-term distribution costs in France.
Zydus Lifesciences Limited, through its subsidiary Amplitude SAS, acquired 100% of French medical equipment distributor Aptitude Orthopedie for approximately ₹3.99 Crore. The acquisition aims to internalize commercial capabilities and reduce long-term distribution costs.